menu
    • menu
    [{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Oxprenolol","moa":"Beta-2 adrenergic receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Faraday Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Oxprenolol","moa":"Beta-2 adrenergic receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Faraday Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Faraday Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"OV350","moa":"KCC2 transporter","graph1":"Neurology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.22,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.22,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Ovid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AstraZeneca \/ Ovid Therapeutics"},{"orgOrder":0,"company":"Neuro-Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NBP14","moa":"nACh-alpha-7 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuro-Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuro-Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Neuro-Bio \/ Undisclosed"},{"orgOrder":0,"company":"Nutrapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"RPI-78M","moa":"Nicotinic acetylcholine receptor (nAChR)","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutrapharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrapharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nutrapharma \/ Undisclosed"},{"orgOrder":0,"company":"AviadoBio","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Series A Financing","leadProduct":"AVB-PGRN","moa":"PGRN","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"AviadoBio \/ New Enterprise Associates","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio \/ New Enterprise Associates"},{"orgOrder":0,"company":"Alchemab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"ATLX-1282","moa":"UNC5C","graph1":"Neurology","graph2":"Preclinical","graph3":"Alchemab","amount2":0.41999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Alchemab \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Alchemab \/ Eli Lilly"},{"orgOrder":0,"company":"Ossianix","sponsor":"Attralus","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody-peptide Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Ossianix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ossianix \/ Attralus","highestDevelopmentStatusID":"4","companyTruncated":"Ossianix \/ Attralus"},{"orgOrder":0,"company":"Bloomsbury Genetic Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BGT-DTDS","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloomsbury Genetic Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bloomsbury Genetic Therapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bloomsbury Genetic Therapies \/ Undisclosed"},{"orgOrder":0,"company":"EpilepsyGTx","sponsor":"UCL Technology Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"EPY201","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"EpilepsyGTx","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"EpilepsyGTx \/ UCL Technology Fund","highestDevelopmentStatusID":"4","companyTruncated":"EpilepsyGTx \/ UCL Technology Fund"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-204","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Orchard Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstronauTx","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"AstronauTx","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"AstronauTx \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"AstronauTx \/ Novartis Venture Fund"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"ALS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ ALS Foundation","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ ALS Foundation"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Mission Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ Omega Funds"},{"orgOrder":0,"company":"TRIMTECH Therapeutics","sponsor":"Cambridge Innovation Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"TRIMTECH Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"TRIMTECH Therapeutics \/ Cambridge Innovation Capital","highestDevelopmentStatusID":"4","companyTruncated":"TRIMTECH Therapeutics \/ Cambridge Innovation Capital"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biodexa Pharmaceuticals \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Biodexa Pharmaceuticals \/ Midatech Pharma"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amphista Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Amphista Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lario Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Lario Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lario Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Lario Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRG Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alchemab

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Alchemab

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATLX-1282

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $415.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Alchemab Inks $415M Licensing Deal with Eli Lilly for ATLX-1282 Development

                            Details : Under the licensing agreement, Alchemab will be taking the programme through early Phase 1 clinical trials of ATLX-1282 after which Lilly will lead all further development and commercialisation.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            May 06, 2025

                            Lead Product(s) : ATLX-1282

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Eli Lilly

                            Deal Size : $415.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TRIMTECH Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            TRIMTECH Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Cambridge Innovation Capital

                            Deal Size : $31.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            TRIMTECH Therapeutics Raises $31M Seed Funding

                            Details : The investment will support development of the Company’s growing pipeline of potent, CNS penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 05, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Cambridge Innovation Capital

                            Deal Size : $31.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tiziana Life Sciences

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tiziana Life Sciences

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : ALS Association

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Tiziana Awarded ALS Trial Grant by ALS Association for Groundbreaking Study

                            Details : The grant will fund a clinical trial of two doses of Tiziana’s novel and patented candidate, intranasal TZLS-401 (foralumab), evaluating the safety of disease improvement in ALS.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            November 19, 2024

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : ALS Association

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NRG Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NRG Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NRG5051

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NRG Selects NRG5051 Candidate with Michael J. Fox Foundation Grant for mPTP

                            Details : NRG5051 is a first-in-class inhibitor of the mPTP and is designed to penetrate the brain when taken orally. It is being evaluated for the treatment of Parkinson's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 31, 2024

                            Lead Product(s) : NRG5051

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NRG Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NRG Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : ALS Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NRG Therapeutics Receives Grant from Target ALS for ALS/MND Treatments

                            Details : The funding will be used to support the discovery program focused on developing mPTP inhibitors as novel treatments for amyotrophic lateral sclerosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 05, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : ALS Foundation

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Actimed Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Actimed Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxprenolol

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Actimed Therapeutics Granted FDA Orphan Drug Status for ALS Treatment ACM-002

                            Details : ACM-002 (S-oxprenolol) has demonstrated slowing disease progression, improvement in survival, attenuation of muscle loss, motor neuron protection in amyotrophic lateral sclerosis (ALS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 04, 2024

                            Lead Product(s) : Oxprenolol

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lario Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Lario Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Lario Therapeutics Awarded $6M Grant from Michael Fox Foundation for Parkinson’s Research

                            Details : The grant will be used to fund Lario’s preclinical programme investigating selective CaV2.3 calcium channel inhibition as a novel and disease-modifying approach for treatment of Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 22, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            EpilepsyGTx

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            EpilepsyGTx

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPY201

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : UCL Technology Fund

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            EpilepsyGTx Raises $10 Million for CTA-Enabling Nonclinical Package for EPY201

                            Details : The funds raised will be used to complete the preclinical studies for EpilepsyGTx’ lead gene therapy program EPY201, for the treatment of focal refractory epilepsy.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            June 24, 2024

                            Lead Product(s) : EPY201

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : UCL Technology Fund

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Amphista Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Amphista Therapeutics

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amphista Shows New Data for Efficacy and CNS Activity of Targeted Protein Degraders

                            Details : Amphista Therapeutics is developing an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader. It is being evaluated in preclinical studies for neurodegenerative diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 24, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AstronauTx

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            AstronauTx

                            United Kingdom arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Novartis Venture Fund

                            Deal Size : $61.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            AstronauTx Closes £48 Million ($61 Million) Series A Financing to Create New Treatments for Alzheimer's Disea...

                            Details : The financing will be used to advance a portfolio small-molecule drugs, including a clinical study in patients with Alzheimer's disease for the lead programme.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Novartis Venture Fund

                            Deal Size : $61.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth